1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B-cell lymphoma
    Meeting Abstract

    Mondello, P.; Tarantelli, C.; Cascione, L.; Arribas, A.; Rinaldi, A.; Younes, A.; Bertoni, F.
    Blood (2019)

    Fulltext@MSK | Save
  • ABVD versus escalated BEACOPP in advanced stage Hodgkin's lymphoma: Results from a retrospective, multicenter European study
    Meeting Abstract

    Mondello, P.; Dogliotti, I.; Bohn, J. P.; Cavallo, F.; Ferrero, S.; Botto, B.; Cerchione, C.; Nappi, D.; De Lorenzo, S.; Martinelli, G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Combinatorial genetics uncovers novel targets for the treatment of Npm1/cohesin mutated AML
    Meeting Abstract

    Meyer, A. E.; Stelloh, C.; Fisher, J. B.; Pulakanti, K.; Vassiliou, G. S.; Viny, A. D.; Levine, R. L.; Rao, S.
    Blood (2019)

    Fulltext@MSK | Save
  • A Phase 1/1b dose-escalation trial evaluating CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, in subjects with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Mobasher, M.; Miller, R. A.; Janc, J. W.; Kwei, L.; Buggy, J. J.; Luciano, G.; Mohammady, A.; Kim, W. S.; Kim, Y. H.; Khodadoust, M. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
    Meeting Abstract

    Menghrajani, K.; Cai, S. F.; Devlin, S. M.; Armstrong, S. A.; Piekarz, R.; Rudek, M.; Tallman, M. S.; Stein, E. M.
    Blood (2019)

    Fulltext@MSK | Save
  • POLARGO: A randomized phase III study evaluating polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma who had received one or more previous therapies
    Meeting Abstract

    McMillan, A. K.; Matasar, M. J.; Sancho, J. M.; Viardot, A.; Hernandez, J.; Perretti, T.; Haioun, C.
    Blood (2019)

    Fulltext@MSK | Save
  • In human visualization of ibrutinib-induced CLL compartment shift
    Meeting Abstract

    Mayerhoefer, M. E.; Haug, A.; Jaeger, U.; Kazianka, L.; Pichler, V.; Pfaff, S.; Wester, H. J.; Hacker, M.; Staber, P. B.
    Blood (2019)

    Fulltext@MSK | Save
  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways
    Meeting Abstract

    Melgar, K. M.; Jones, L. M.; Walker, M.; Bolanos, L. C.; Hueneman, K.; Wunderlich, M.; Jiang, J. K.; Wilson, K.; Zhang, X.; Sutter, P.; more...
    Blood (2019)

    Fulltext@MSK | Save